Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: A case report
Abstract We report a case of isolated adrenocorticotropin deficiency caused by pembrolizumab. This condition can be fatal, but its rarity causes under‐recognition. Oncologists should pay attention to adrenal insufficiency due to pembrolizumab.
Main Authors: | Koichiro Yamamoto, Kazuki Tokumasu, Kosuke Oka, Kou Hasegawa, Fumio Otsuka |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4305 |
Similar Items
-
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
by: Sahityasri Thapi, et al.
Published: (2019-09-01) -
Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study
by: E. V. Poddubskaya, et al.
Published: (2019-12-01) -
Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
by: Jingli Lu, et al.
Published: (2019-12-01) -
Low-dose adrenocorticotropin test in patients with the Acquired Immunodeficiency Syndrome
by: Fernando H. Wolff, et al. -
DELAY IN DIAGNOSIS OF MALARIA BECAUSE OF IMPROPER EFFECTS OF ANTIBIOTIC THERAPY
by: M. Jalali Tabatabai, et al.
Published: (2000-12-01)